User menu

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.

Bibliographic reference Czuczman, Myron S ; Kahanic, Stephen ; Forero, Andres ; Davis, Glen ; Munteanu, Mihaela ; et. al. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.. In: Annals of Hematology, Vol. 94, no.4, p. 633-641 (2015)
Permanent URL
  1. Rummel Mathias J, Niederle Norbert, Maschmeyer Georg, Banat G Andre, von Grünhagen Ulrich, Losem Christoph, Kofahl-Krause Dorothea, Heil Gerhard, Welslau Manfred, Balser Christina, Kaiser Ulrich, Weidmann Eckhart, Dürk Heinz, Ballo Harald, Stauch Martina, Roller Fritz, Barth Juergen, Hoelzer Dieter, Hinke Axel, Brugger Wolfram, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, 10.1016/s0140-6736(12)61763-2
  2. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276
  3. Marcus R., CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, 10.1182/blood-2004-08-3175
  4. Flinn I. W., van der Jagt R., Kahl B. S., Wood P., Hawkins T. E., MacDonald D., Hertzberg M., Kwan Y.-L., Simpson D., Craig M., Kolibaba K., Issa S., Clementi R., Hallman D. M., Munteanu M., Chen L., Burke J. M., Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, 10.1182/blood-2013-11-531327
  5. Leoni L. M., Bailey B., Reifert J., Bendall H. H., Zeller R. W., Corbeil J., Elliott G., Niemeyer C. C., Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents, 10.1158/1078-0432.ccr-07-1061
  6. Tageja Nishant, Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma, 10.4137/cmo.s6085
  7. Czuczman Myron S., Hess Georg, Gadeberg Ole V., Pedersen Lars M., Goldstein Nancy, Gupta Ira, Jewell Roxanne C., Lin Thomas S., Lisby Steen, Strange Claus, Windfeld Kristian, Viardot Andreas, , Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma, 10.1111/j.1365-2141.2012.09086.x
  8. Hagenbeek A., Gadeberg O., Johnson P., Moller Pedersen L., Walewski J., Hellmann A., Link B. K., Robak T., Wojtukiewicz M., Pfreundschuh M., Kneba M., Engert A., Sonneveld P., Flensburg M., Petersen J., Losic N., Radford J., First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial, 10.1182/blood-2007-10-117671
  9. Lemery S. J., Zhang J., Rothmann M. D., Yang J., Earp J., Zhao H., McDougal A., Pilaro A., Chiang R., Gootenberg J. E., Keegan P., Pazdur R., U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab, 10.1158/1078-0432.ccr-10-0570
  10. Teeling J. L., Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas, 10.1182/blood-2004-01-0039
  11. Teeling J. L., Mackus W. J. M., Wiegman L. J. J. M., van den Brakel J. H. N., Beers S. A., French R. R., van Meerten T., Ebeling S., Vink T., Slootstra J. W., Parren P. W. H. I., Glennie M. J., van de Winkel J. G. J., The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20, 10.4049/jimmunol.177.1.362
  12. Czuczman M. S., Fayad L., Delwail V., Cartron G., Jacobsen E., Kuliczkowski K., Link B. K., Pinter-Brown L., Radford J., Hellmann A., Gallop-Evans E., DiRienzo C. G., Goldstein N., Gupta I., Jewell R. C., Lin T. S., Lisby S., Schultz M., Russell C. A., Hagenbeek A., , Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study, 10.1182/blood-2011-09-378323
  13. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
  14. Trotman Judith, Fournier Marion, Lamy Thierry, Seymour John Francis, Sonet Anne, Janikova Andrea, Shpilberg Ofer, Gyan Emmanuel, Tilly Hervé, Estell Jane, Forsyth Cecily, Decaudin Didier, Fabiani Bettina, Gabarre Jean, Salles Bruno, Van Den Neste Eric, Canioni Danielle, Garin Etienne, Fulham Michael, Vander Borght Thierry, Salles Gilles, Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants, 10.1200/jco.2011.35.0736